Login to Your Account

Other News To Note

Wednesday, February 1, 2012

• Circadian Technologies Ltd., of Melbourne, Australia, said preclinical data showed that VEGF-C blockade, through administration of Circadian's lead candidate VGX-100, a human antibody, significantly improved corneal graft survival in an animal model.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription